Alan Kohler from 'The Constant Investor' covers Patrys, page-5

"I also know that in this field, and I’ll be really specific here, when we talk about pre-clinical cancer antibodies there is an awful lot of commercial interest. Over the last four years or so you can see deals worth up to billions of dollars with upfront up to $250 million for preclinical assets. We are definitely a pre-clinical asset at the moment, one could certainly see a path forward where this asset might be taken away from us before it got to the clinic or perhaps we would entertain a model where we had a co-development path".

James Campbell (CEO), 2018.


James indicating that PAB might not even make it to clinical trials before being taken over by a much larger company